Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer

Academic Article

Abstract

  • Twelve patients with metastatic colon cancer were treated with 131I- chimeric B72.3 (IgG-4) at total doses of 28 or 36 mCi/m2 in two or three weekly fractions. Bone marrow suppression was the only significant side effect. The degree of bone marrow suppression adjusted for whole-body dose was modestly but statistically significantly (p = 0.04) less than that seen with identical doses given as a single infusion for the total dose of 36 mCi/m2. Nine of twelve patients developed an antibody response to ch B72.3, which altered the kinetics of radiolabeled antibody in four patients given a second course of therapy. One patient had a minor response that lasted 4 mo. Fractionation of this particular radiolabeled antibody at the dose schedule used produced a modest increase in the therapeutic window in regard to administered dose.
  • Authors

    Published In

    Author List

  • Meredith RF; Khazaeli MB; Liu T; Plott G; Wheeler RH; Russell C; Colcher D; Schlom J; Shochat D; LoBuglio AF
  • Start Page

  • 1648
  • End Page

  • 1653
  • Volume

  • 33
  • Issue

  • 9